No Data
No Data
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmac
Kangnai De Life Science (CNTB.US) is trapped on the eve of commercialization: the founder left and the stock price fell more than 30% in seven days.
On June 21st, the stock price of Kangnaide Biotechnology (CNTB.US) fell by 3.95%. This is the seventh trading day since its Chinese founding team completely left the company, and also the seventh trading day of the company's new round of stock price decline. During this period, the company's stock price has accumulated a 31.86% decline.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at $15.0 million. JanOne (NASDAQ:JAN) stock rose 26.07% to $3.24. The co
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $8 price target.
Connect Biopharma Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/13/2024 325.53% HC Wainwright & Co. $8 → $8 Reiterates Buy → Buy 04/17/2024 325.53% HC Wainwright & Co.
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Emily Bodnar maintains $Connect Biopharma(CNTB.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 39.3%